Citadel Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-15,800
| Closed | -$595K | – | 14985 |
|
|
2021
Q1 | $595K | Sell |
15,800
-2,100
| -12% | -$52.4K | ﹤0.01% | 9306 |
|
|
2020
Q4 | $304K | Buy |
+17,900
| New | +$224K | ﹤0.01% | 9057 |
|
|
2019
Q2 | – | Sell |
-29,700
| Closed | -$398K | – | 10162 |
|
|
2019
Q1 | $398K | Buy |
+29,700
| New | +$339K | ﹤0.01% | 7171 |
|
|
2018
Q4 | – | Sell |
-15,000
| Closed | -$209K | – | 10061 |
|
|
2018
Q3 | $209K | Buy |
+15,000
| New | +$223K | ﹤0.01% | 8155 |
|
|
2018
Q1 | – | Sell |
-12,500
| Closed | -$274K | – | 9009 |
|
|
2017
Q4 | $274K | Sell |
12,500
-13,800
| -52% | -$444K | ﹤0.01% | 6609 |
|
|
2017
Q3 | $1.08M | Sell |
26,300
-5,700
| -18% | -$179K | ﹤0.01% | 4208 |
|
|
2017
Q2 | $964K | Sell |
32,000
-2,200
| -6% | -$68.7K | ﹤0.01% | 4128 |
|
|
2017
Q1 | $1.24M | Buy |
+34,200
| New | +$1.51M | ﹤0.01% | 3703 |
|
|
2016
Q3 | – | Sell |
-8,800
| Closed | -$364K | – | 7991 |
|
|
2016
Q2 | $364K | Sell |
8,800
-3,100
| -26% | -$135K | ﹤0.01% | 4941 |
|
|
2016
Q1 | $483K | Buy |
11,900
+6,100
| +105% | +$210K | ﹤0.01% | 4462 |
|
|
2015
Q4 | $241K | Buy |
+5,800
| New | +$194K | ﹤0.01% | 5540 |
|
Citadel Advisors's FPRX Position: Q1 2021 in Review
Citadel Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 706,864 shares — an estimated $17.6M sold.
Citadel Advisors first reported a position in FPRX in Q3 2014 and held it in 19 quarters. The position peaked at $12M in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.
- Citadel Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
- Citadel Advisors sold 706,864 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $17.6M.
- Citadel Advisors first reported a position in Five Prime Therapeutics, Inc. in Q3 2014 and held it in 19 quarters.
- Citadel Advisors's Five Prime Therapeutics, Inc. position peaked at $12M in Q4 2020.
- 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.
Based on Citadel Advisors's 13F filing for Q1 2021, filed 17 May 2021.